Gold’s “dead” trade may be the most loudly buried one on the board

Gold's post-crisis drop pattern has repeated after every major oil shock for 50 years

The source notes that everyone is calling gold dead right now, and that the same thing happened in 1973, 1979, 1991, 2001, and after Ukraine — gold fell first every single time, then recovered to higher highs every single time. Gold started a decade-long run from $250 to $1,900, and then after the Ukraine conflict, gold finally broke $2,000. More recently, gold hit an all-time high of around $5,600 in January, then dropped roughly 20% after the Iran conflict, while headlines declared the gold trade finished. The source's position: a gold drop after a crisis is not the end of the story.

Gobble's Take: The source documents the same post-shock drop-and-recovery sequence repeating across five decades — the current drop fits the same pattern. Source: Gold and Silver Trend in the Stock Market 2026

Copper just broke into price discovery after a 30-year-style grind

Copper is now described as hitting new historical highs on COMEX futures, with the breakout framed as a structural deficit moving from the background into the foreground. The note says copper is not a speculative growth stock-style mover; it advances slowly, then persistently, and this kind of multi-decade resistance break changes the question from whether the thesis is real to how far it can run before supply responds.

Gobble's Take: Copper didn’t kick the door in — it finally unlocked it, and that’s often the more interesting move. Source: Copper Is Entering Its Next Great Bull Market!

$BCYC is a catalyst-driven setup awaiting key clinical readouts

Bicycle Therapeutics is focused on a series of clinical readouts centered on nuzefatide pevedotin, a Bicycle Drug Conjugate targeting EphA2, being evaluated in second-line and later pancreatic ductal adenocarcinoma (PDAC). The pipeline also includes zelenectide pevedotin (formerly BT8009), a BDC targeting Nectin-4, a well-validated tumor antigen, with the randomized Duravelo-2 study ongoing. Bulls point to the differentiated safety profile, selective target engagement, favorable pharmacokinetics, and tumor penetration. Bears argue the thesis still relies on early-stage datasets and mechanistic rationale rather than definitive efficacy evidence. The upcoming PDAC and Duravelo-2 readouts are increasingly viewed as company-defining events that could drive substantial re-rating in either direction.

Gobble's Take: The clinical data from PDAC and Duravelo-2 will determine whether Bicycle molecules translate differentiated pharmacology into meaningful outcomes.

Source: BIOTECH MARKET RESEARCH $BCYC | Ep. 1019

In Case You Missed It

Yesterday's top stories:

• Macro mood is sour, but the tape is less cooperative with the doom crowd
• While long-term history labels June as a flat, neutral month, the last decade has transformed it into a bullish launchpad for equities, with SPY averaging a +0.85% gain and closing green 9 of the last 10 years.
• Fox drops hard, while a handful of stocks are sprinting